농가진 치료 시장 : 투여 경로별, 환자 유형별, 약물 종류별, 유통 채널별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 점유율, 예측(2025-2032년)

Impetigo Treatment Market size was valued at US$ 778 Million in 2024, expanding at a CAGR of 5.8% from 2025 to 2032.

The Impetigo Treatment Market includes pharmaceuticals, topical antibiotics, antiseptics, and advanced dermatology solutions for treating impetigo, a contagious bacterial skin infection that primarily affects children. The rising prevalence of skin infections linked to poor hygiene, overcrowding, and increased bacterial resistance is a major driver of market growth. A key market trend is the shift toward non-antibiotic and antiseptic-based therapies, which reflect global efforts to combat antimicrobial resistance. However, the market faces a significant challenge in the form of rising MRSA (methicillin-resistant Staphylococcus aureus) infections, which reduce the efficacy of conventional antibiotics and complicate treatment protocols. Despite this, significant opportunities arise from innovation in combination therapies, novel topical formulations, and faster-acting antimicrobial agents, allowing for more targeted and resistant-free treatment options. Together, these factors position the impetigo treatment market for steady growth as healthcare systems prioritize skin infection control and more effective antimicrobial use.

Impetigo Treatment Market- Market Dynamics

Rising Focus on Advanced Dermatology and Infectious Disease Management

The rise in antibiotic resistance and skin infection prevalence is a major driver of the Impetigo Treatment Market. To ensure successful treatment outcomes, healthcare systems are prioritizing faster diagnostics, improved formulations, and advanced antimicrobial solutions. This trend is bolstered by strategic industry developments that increase research capacity. For example, in January 2020, Novartis' acquisition of The Medicines Company significantly strengthened its therapeutic pipeline and demonstrated the industry's commitment to developing infectious disease solutions. Although the acquisition focused on inclisiran, it reflects a larger push toward high-innovation portfolios, indirectly accelerating progress in dermatology and skin-infection therapeutics, including impetigo.

Impetigo Treatment Market- Segmentation Analysis:

The Global Impetigo Treatment Market is segmented by Route of Administration, Patient Type, Drug Class, Distribution Channel and Region.

According to the Route of Administration, the oral segment is important in the Impetigo Treatment Market because it works well for moderate to severe infections, recurrent cases, and situations where topical antibiotics fail. Oral formulations such as amoxicillin-clavulanate, clindamycin, and macrolides have systemic action, which aids in the elimination of deeper or widespread infections. Growing antimicrobial innovation and combination therapies also contribute to this segment's demand. In March 2020, Menlo Therapeutics' merger with Foamix Pharmaceuticals strengthened its dermatology portfolio, indirectly supporting improved antibiotic and anti-infective therapy development for skin diseases such as impetigo. Such strategic alliances strengthen R&D capabilities for more potent oral formulations, propelling this segment forward.

By Distribution Channel, the hospital pharmacy segment remains critical as hospitals treat more severe, rapidly spreading, or immunocompromised impetigo cases that necessitate prompt access to validated medications. This segment benefits from structured antibiotic stewardship, specialist consultations, and access to advanced diagnostics. The increase in hospital-based dermatology services and outbreak management protocols is also driving the segment. For instance, in November 2021, NovaBay Pharmaceuticals' acquisition of DERMAdoctor expanded the company's dermatology-focused product distribution through professional channels, including hospitals. Such corporate moves increase the availability of dermatologist-recommended formulations in hospital pharmacies, thereby improving patient access to reliable impetigo treatment options.

Impetigo Treatment Market- Geographical Insights

North America commands the Impetigo Treatment Market, owing to the high prevalence of bacterial skin infections and widespread public awareness of impetigo, particularly among children. The region has an advanced healthcare infrastructure, widespread access to dermatologists, and well-established reimbursement systems. In addition, strong government-backed public health programs and widespread availability of both branded and generic prescription medications have accelerated market adoption. A high level of healthcare spending, routine clinical screenings, and rapid diagnostic capabilities all help to detect impetigo cases early and treat them effectively. Additionally, the active involvement of major pharmaceutical companies in dermatology R&D, particularly in the fight against antibiotic resistance, reinforces North America's market leadership.

United States Impetigo Treatment Market- Country Insights

The United States is one of the most influential markets for impetigo treatment, thanks to a robust healthcare infrastructure, high infection awareness, and widespread access to dermatology services. The country experiences a consistent incidence of bacterial skin infections, particularly among children, fueling ongoing demand for topical and oral antibiotics. In addition, the United States prioritizes early diagnosis through routine pediatric screenings, which allows for timely and effective treatment. Strong pharmaceutical innovation, backed up by advanced R&D capabilities and streamlined regulatory pathways, shapes the market even further.

For example, in June 2025, Sanofi received FDA approval for Dupixent (dupilumab) to treat bullous pemphigoid, an inflammatory skin disease. Although not a direct impetigo treatment, this milestone highlights the nation's growing dermatology innovation landscape, opening up new avenues for managing associated skin infections and improving long-term patient outcomes.

Impetigo Treatment Market- Competitive Landscape:

The competitive landscape of the impetigo treatment market is distinguished by the presence of several key players involved in the development, manufacturing, and marketing of antibiotics and other treatment options. Companies are focusing on strategic initiatives like mergers and acquisitions, partnerships, and collaborations to improve their market position and product portfolio. Many companies prioritize the development of new antibiotic formulations and combination therapies as a means of addressing antibiotic resistance and improving treatment outcomes. For instance, in January 2022, Pfizer received approval for CIBINQO (abrocitinib), an oral inhibitor for the treatment of patients with moderate to severe dermatitis. CIBINQO will be an important new oral option for those who have yet to find relief. CIBINQO demonstrated good efficacy in clearing skin, reducing itching, and managing the severity and scope of eczema, with a benefit-risk profile that supports its use in the FDA-approved patient population.

Recent Developments:

In May 2024, NovaBay Pharmaceuticals has launched a dermatology service via telehealth for remote consultation and prescription to treat impetigo. The online service improves access, particularly in rural and underserved markets, by allowing clinicians to diagnose and treat impetigo remotely. The service is part of a trend toward hybrid dermatologic treatment models and allows patients to easily access topically prescribed antibiotics.

In June 2025, Ferrer announced the successful completion of its Phase III trial of Ozenoxacin 1% cream to treat impetigo in pediatric and adult patients, which demonstrated improved clinical and bacteriological responses compared to placebo. The cream showed early improvement on days 3-4 and was well tolerated in geographically dispersed centers in the United States, Germany, South Africa, and Ukraine. With this success, Ozenoxacin moves to the forefront of the near-term global market presence.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as following:

GLOBAL IMPETIGO TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• GlaxoSmithKline plc
• Ranbaxy Laboratories Limited
• Roche Holding AG
• Karalex Pharma, LLC
• Teva Pharmaceutical Industries Ltd
• Pfizer, Inc
• SANDOZ GmbH
• NovaBay Pharmaceuticals, Inc.
• Lupin Limited
• Leo Pharma A/S
• Taro Pharmaceutical Industries Ltd
• Others

GLOBAL IMPETIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

• Topical
• Oral

GLOBAL IMPETIGO TREATMENT MARKET, BY PATIENT TYPE- MARKET ANALYSIS, 2019 - 2032

• Children
• Elderly
• Adults

GLOBAL IMPETIGO TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

• Cephalosporins
• Quinolones
• Sulfonamides
• Fusidane
• Lincosamide
• Penicillin
• Tetracycline
• Others

GLOBAL IMPETIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

GLOBAL IMPETIGO TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Impetigo Treatment Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Impetigo Treatment Market Snippet by Route of Administration
  • 2.1.2. Impetigo Treatment Market Snippet by Patient Type
  • 2.1.3. Impetigo Treatment Market Snippet by Drug Class
  • 2.1.4. Impetigo Treatment Market Snippet by Distribution Channel
  • 2.1.5. Impetigo Treatment Market Snippet by Country
  • 2.1.6. Impetigo Treatment Market Snippet by Region
• 2.2. Competitive Insights

3. Impetigo Treatment Key Market Trends

• 3.1. Impetigo Treatment Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Impetigo Treatment Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Impetigo Treatment Market Opportunities
• 3.4. Impetigo Treatment Market Future Trends

4. Impetigo Treatment Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Impetigo Treatment Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Impetigo Treatment Market Landscape

• 6.1. Impetigo Treatment Market Share Analysis, 2024
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Impetigo Treatment Market - By Route of Administration

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
  • 7.1.2. Topical
  • 7.1.3. Oral

8. Impetigo Treatment Market - By Patient Type

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Patient Type, 2024 & 2032 (%)
  • 8.1.2. Children
  • 8.1.3. Elderly
  • 8.1.4. Adults

9. Impetigo Treatment Market - By Drug Class

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
  • 9.1.2. Cephalosporins
  • 9.1.3. Quinolones
  • 9.1.4. Sulfonamides
  • 9.1.5. Fusidane
  • 9.1.6. Lincosamide
  • 9.1.7. Penicillin
  • 9.1.8. Tetracycline
  • 9.1.9. Others

10. Impetigo Treatment Market - By Distribution Channel

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By Patient Type, 2024 & 2032 (%)
  • 10.1.2. Hospital Pharmacies
  • 10.1.3. Retail Pharmacies
  • 10.1.4. Online Pharmacies

11. Impetigo Treatment Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Impetigo Treatment Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Impetigo Treatment Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.9. UK
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.9.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.9.4. UK Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.9.5. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.10. France
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.10.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.10.4. France Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.10.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.11. Italy
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.11.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.11.4. Italy Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.11.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.12. Spain
    • 11.3.12.1. Overview
    • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.12.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.12.4. Spain Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.12.5. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.13. The Netherlands
    • 11.3.13.1. Overview
    • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.13.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.13.4. The Netherlands Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.13.5. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Overview
    • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.15. Russia
    • 11.3.15.1. Overview
    • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.15.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.15.4. Russia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.15.5. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.16. Poland
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.16.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.16.4. Poland Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.16.5. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3.17. Rest of Europe
    • 11.3.17.1. Overview
    • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Impetigo Treatment Key Manufacturers in Asia Pacific
  • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 11.4.5. APAC Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
  • 11.4.6. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.8. China
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.8.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.8.4. China Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.8.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.9. India
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.9.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.9.4. India Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.9.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.13. Indonesia
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.13.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.13.4. Indonesia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.13.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.14. Thailand
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.14.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.14.4. Thailand Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.14.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4.16. Rest of APAC
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.16.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.16.4. Rest of APAC Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 11.5. Latin America (LATAM)
  • 11.5.1. Overview
  • 11.5.2. Impetigo Treatment Key Manufacturers in Latin America
  • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 11.5.5. LATAM Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
  • 11.5.6. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 11.6. Middle East and Africa (MEA)
  • 11.6.1. Overview
  • 11.6.2. Impetigo Treatment Key Manufacturers in Middle East and Africa
  • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.6.4. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 11.6.5. MEA Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
  • 11.6.6. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6.14. Rest of MEA
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.14.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.14.4. Rest of MEA Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Impetigo Treatment Industry

• 12.1. Competitive Benchmarking
  • 12.1.1. Competitive Dashboard
  • 12.1.2. Competitive Positioning
• 12.2. Company Profiles
  • 12.2.1. GlaxoSmithKline plc
  • 12.2.2. Ranbaxy Laboratories Limited
  • 12.2.3. Roche Holding AG
  • 12.2.4. Karalex Pharma, LLC
  • 12.2.5. Teva Pharmaceutical Industries Ltd
  • 12.2.6. Pfizer, Inc
  • 12.2.7. SANDOZ GmbH
  • 12.2.8. NovaBay Pharmaceuticals, Inc.
  • 12.2.9. Lupin Limited
  • 12.2.10. Leo Pharma A/S
  • 12.2.11. Taro Pharmaceutical Industries Ltd
  • 12.2.12. Others

13. 360 Degree AnalystView

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us